

August 10, 2021

VIA EDGAR

United States Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549

Attn: Christine Westbrook  
Tracey Houser  
Daniel Gordon

**Re: Dermata Therapeutics, Inc.  
Registration Statement on Form S-1  
File No. 333- 256997**

**Acceleration Request**

**Requested Date: August 12, 2021**

**Requested Time: 5:00 p.m. Eastern Time**

Dear Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Dermata Therapeutics, Inc. (the "Company") hereby requests that the above-referenced Registration Statement (the "Registration Statement") be declared effective by the Securities and Exchange Commission (the "Commission") at the "Requested Date" and "Requested Time" set forth above or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff.

Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973)597-2476 to confirm the effectiveness of the Registration Statement or with any questions.

Sincerely,

DERMATA THERAPEUTICS, INC.

By: /s/ Gerald T. Proehl

Name: Gerald T. Proehl

Title: Chief Executive Officer